Pantoprazole 40mg, Amoxicillin and Levofloxacin — Competitive Intelligence Brief

Pantoprazole 40mg, Amoxicillin and Levofloxacin (Pantoprazole 40mg, Amoxicillin and Levofloxacin) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton pump inhibitor + antibiotic combination. Area: Gastroenterology.

phase 3 Proton pump inhibitor + antibiotic combination H+/K+-ATPase (pantoprazole); bacterial DNA gyrase and topoisomerase IV (levofloxacin); bacterial cell wall (amoxicillin) Gastroenterology Small molecule

Target snapshot

Pantoprazole 40mg, Amoxicillin and Levofloxacin (Pantoprazole 40mg, Amoxicillin and Levofloxacin) — Ain Shams University. This is a triple-therapy combination that suppresses gastric acid while simultaneously targeting bacterial pathogens associated with peptic ulcer disease and gastritis.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pantoprazole 40mg, Amoxicillin and Levofloxacin TARGET	Pantoprazole 40mg, Amoxicillin and Levofloxacin	Ain Shams University	phase 3	Proton pump inhibitor + antibiotic combination	H+/K+-ATPase (pantoprazole); bacterial DNA gyrase and topoisomerase IV (levofloxacin); bacterial cell wall (amoxicillin)
Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Omeprazole, Amoxicillin, Metronidazole and Clarithromycin	Al-Azhar University	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (omeprazole); bacterial ribosome and cell wall (amoxicillin, clarithromycin); bacterial DNA (metronidazole)
Vonoprazan + amoxicillin + clarithromycin	Vonoprazan + amoxicillin + clarithromycin	The Third Xiangya Hospital of Central South University	marketed	Proton pump inhibitor + antibiotic combination	H+ K+-ATPase (vonoprazan); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin)
Lansoprazole/Amoxicillin/Clarithromycin	Lansoprazole/Amoxicillin/Clarithromycin	HK inno.N Corporation	marketed	Proton pump inhibitor + antibiotic combination	H+ ATPase (lansoprazole); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)
Lansoprzole+Amoxicillin+Clarithromycin	Lansoprzole+Amoxicillin+Clarithromycin	Korean College of Helicobacter and Upper Gastrointestinal Research	marketed	Proton pump inhibitor + antibiotic combination (triple therapy)	H+ ATPase (lansoprazole); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin)
Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	American University of Beirut Medical Center	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (rabeprazole); bacterial ribosome and DNA (metronidazole, clarithromycin); bacterial cell wall (amoxicillin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proton pump inhibitor + antibiotic combination class)

1. Ain Shams University · 1 drug in this class
2. HK inno.N Corporation · 1 drug in this class
3. The Third Xiangya Hospital of Central South University · 1 drug in this class